KMT2A and plasma cell myeloma: OT-82 suppressed the tumor growth of subcutaneous xenografts of acute myeloid leukemia (AML) (MV4-11), erythroleukemia (HEL92.1.7), Burkitt lymphoma (Ramos), and multiple myeloma (RPMI 8226), and prolonged survival of mice with systemic xenografts of AML (MV4-11), erythroleukemia (HEL92.1.7), infant MLL-arranged ALL (MLL-2) and with patient-derived xenografts (PDX) of high risk ALL [109,154].